Cyclosporine A-induced gingival hyperplasia pemphigus vulgaris: literature review and report of a case.
Gingival hyperplasia appears in 8% to 85% of patients treated with cyclosporine. Most studies show an association between oral hygiene status and the prevalence and severity of this gingival overgrowth. Thus, besides attempting to substitute this drug with another whenever possible, treatment usually involves maintenance of strict oral hygiene coupled with scaling and root planing and removal of iatrogenic factors. Sometimes a second treatment phase involving periodontal surgery is necessary. Cyclosporine-induced gingival overgrowth has been mainly described in post-organ transplant patients. The present case describes, for the first time, a severe form of cyclosporine-induced gingival overgrowth arising in a 15 year-old male with pemphigus vulgaris. Periodontal treatment included oral hygiene and scaling and root planing under local anesthesia. There was a significant reduction in gingival enlargement, as well as a reduction in plaque levels and inflammation. Cessation of drug administration, combined with continuous periodontal treatment, brought further improvement. This successful conservative treatment of cyclosporine-induced gingival overgrowth in a pemphigus vulgaris patient suggests that early diagnosis and comprehensive treatment of these lesions may yield good response and reduce the need for periodontal surgery.
Oettinger-Barak
O
O
Unit of Periodontology, Rambam Medical Center, Haifa, Israel. barakori@zahav.net.il
Machtei
E E
EE
Peled
M
M
Barak
S
S
L-Naaj
I A
IA
Laufer
D
D
D000293:Adolescent; D016572:Cyclosporine / Q000009:adverse effects*; D003773:Dental Plaque / Q000517:prevention & control; D012534:Dental Scaling; D005500:Follow-Up Studies; D005884:Gingival Hemorrhage / Q000517:prevention & control; D005885:Gingival Hyperplasia / Q000139:chemically induced* / Q000628:therapy; D005891:Gingivitis / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D009910:Oral Hygiene; D010349:Patient Compliance; D010392:Pemphigus / Q000188:drug therapy*; D015995:Prevalence; D016745:Root Planing; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine